January 5, 2021 – Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452
Akston Biosciences and LakePharma, a leading U.S.-based CRDMO serving the biotechnology community with development and production services, announced today that they have established a strategic partnership. LakePharma will manufacture commercial quantities of Akston’s adjuvated COVID-19 vaccine candidate (AKS-452), which is scheduled to begin Phase 1/2 clinical testing later this month. A vaccine for everywhere and everyone in the world, AKS-452 is stable for weeks at room temperature, inexpensive to produce, and suitable for both first-time and booster vaccination.
Click here to view the full press release.